U.S. National Library of Medicine
National Center for Biotechnology Information

NLM Citation: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Indium 111 Ibritumomab Tiuxetan. [Updated 2019 Jun 30].
Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/

Indium 111 Ibritumomab Tiuxetan

Revised: June 30, 2019.

CASRN: 1607828-40-9

Drug Levels and Effects

Summary of Use during Lactation

Information in this record refers to the use of indium 111 ibritumomab tiuxetan as a diagnostic agent. No information is available on the use of indium 111 ibritumomab tiuxetan during breastfeeding. Because of the long half-life of indium 111 and the potential for serious adverse reactions in nursing infants, the manufacturer recommends not administering the drug in women who wish to continue breastfeeding. If the drug is administered to a nursing mother, breastfeeding should be discontinued. If the drug is given, breastfeeding should be discontinued.

Drug Levels

Indium 111 decays by electron capture with 171 keV and 245 keV gamma emissions and a physical half-life of 2.83 days.[1]

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Howe DB, Beardsley M, Bakhsh S. Appendix U. Model procedure for release of patients or human research subjects administered radioactive materials. In, NUREG-1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. Final report. U.S. Nuclear Regulatory Commission Office of Nuclear Material Safety and Safeguards. 2008;9, Rev. 2. Available at: http://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/

Substance Identification

Substance Name

Indium 111 Ibritumomab Tiuxetan

CAS Registry Number

1607828-40-9

Drug Class

Breast Feeding

Lactation

Radiopharmaceuticals

Indium Radioisotopes

Diagnostic Agents